Tekla Advisor Update Webcast

Join us for a webcast with Dr. Daniel R Omstead, Portfolio Manager for the Tekla Funds. Dr. Omstead will provide you a current outlook on the healthcare market, as well as reflections on 2018.

• Review of Tekla Funds in 2018
• A look ahead for healthcare in 2019
• Additional insights regarding healthcare and opportunities that exist today

Featuring

Daniel R. Omstead, PH.D

President and Chief Executive Officer

Dan Omstead is President of TCM and the Funds. Dr. Omstead joined TCM in October 2000. Previously, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, he participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dr. Omstead holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Dr. Omstead is a member of the team responsible for making investments on behalf of the Funds and has overall investment decision responsibility. Dr. Omstead has over sixteen years of investment experience.